Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How would you manage T3N0M0 sarcomatoid carcinoma of the prostate with Adenosquamous differentiation s/p prostatectomy.
Any role for adjuvant therapy with chemotherapy, ADT or radiation?
Related Questions
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
How do you manage prostate cancer in patients that cannot swallow pills?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
What are your top takeaways from ASCO GU 2025?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
Under what circumstances would you treat prostate cancer without a biopsy?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?